Stay updated on the AHA 22 late-breaking data!

In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions. 

What are the key take-aways from AHA 22? What are the most promising findings? How should we understand the new data in the context of patient care?

Discussed trials:
0:29:08: ISCHEMIA-EXTENDed: Follow-Up Interim Report
4:50:25: TRANSFORM-HF: Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure
7:14:01: IRONMAN: Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure with Reduced Ejection Fraction
9:57:30: ECMO-CS: Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
14:53:44: RESPECT-EPA: Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid
17:41:32: PRECISION: Sustained Blood Pressure Lowering Effect with the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results from a Randomized, Controlled Study Including a Withdrawal Phase
20:21:14: BrigHTN: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension
22:38:05: SPYRAL HTN-ON: Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs
29:49:14: EARLY-AF: Early Aggressive Invasive Intervention for Atrial Fibrillation
32:04: DOSE VF: Double Sequential External Defibrillation for Refractory Ventricular Fibrillation

For our full AHA 22 coverage click here.

Producer: David Ramsey